TY  - JOUR
AU  - Cavero, Teresa
AU  - Rabasco, Cristina
AU  - Lopez, Antia
AU  - Roman, Elena
AU  - Avila, Ana
AU  - Sevillano, Angel
AU  - Huerta, Ana
AU  - Rojas-Rivera, Jorge
AU  - Fuentes, Carolina
AU  - Blasco, Miquel
AU  - Jarque, Ana
AU  - Garcia, Alba
AU  - Mendizabal, Santiago
AU  - Gavela, Eva
AU  - Macia, Manuel
AU  - Quintana, Luis F
AU  - Romera, Ana Maria 
AU  - Borrego, Josefa
AU  - Arjona, Emi
AU  - Espinosa, Mario
AU  - Portoles, Jose
AU  - Gracia-Iguacel, Carolina
AU  - Gonzalez-Parra, Emilio
AU  - Aljama, Pedro
AU  - Morales, Enrique
AU  - Cao, Mercedes
AU  - Rodriguez-de-Cordoba, Santiago
AU  - Praga, Manuel
PY  - 2017
DO  - 10.1093/ndt/gfw453
UR  - http://hdl.handle.net/10668/11000
T2  - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
AB  - Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. We identified 29...
LA  - en
PB  - Oxford University Press
KW  - Atypical haemolytic uraemic syndrome
KW  - Complement activation
KW  - Eculizumab
KW  - Thrombotic microangiopathies
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Atypical Hemolytic Uremic Syndrome
KW  - Churg-Strauss Syndrome
KW  - Complement Inactivating Agents
KW  - Creatinine
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Kidney Function Tests
KW  - Lupus Erythematosus, Systemic
KW  - Male
KW  - Middle Aged
KW  - Plasmapheresis
KW  - Platelet Count
KW  - Recurrence
KW  - Renal Insufficiency
KW  - Scleroderma, Systemic
KW  - Thrombotic Microangiopathies
TI  - Eculizumab in secondary atypical haemolytic uraemic syndrome.
TY  - research article
VL  - 32
ER  -